Crinetics Pharmaceuticals Confirms Completion for Half of the Enrolled Patients in the Ongoing Phase 2 ACROBAT Edge Clinical Trial for Paltusotine

• NASDAQ: $CRNX
• Notified: $16.76
• 07:30 EDT